Navigating Initial Treatment Options Quiz

This quiz tests WM Initial Treatment Options and comprehension after viewing the video "Navigating Initial Treatment Options for WM Patients New to Therapy" from 2026 U.S. Educational Forum.

Question Title

1. A newly diagnosed WM patient feels well, has no significant symptoms, and has stable blood counts. What is the most likely recommendation? (Required.)

Begin treatment immediately

Schedule a stem cell transplant

Watch and wait (active monitoring)

Start radiation therapy

Question Title

2. Why do WM specialists often recommend monitoring instead of immediate treatment for patients without symptoms? (Required.)

Treatment is ineffective in WM

There is no evidence that early treatment improves outcomes

Insurance companies require monitoring first

WM always progresses very slowly

Question Title

3. Which of the following may be a reason to start treatment for WM? (Required.)

Significant fatigue caused by WM

Large lymph nodes that could affect organs

Significant anemia or low platelet counts

All of the above

Question Title

4. A patient's IgM level rises above 6,000 mg/dL, but they have no symptoms. Why might some physicians still discuss treatment? (Required.)

Elevated IgM automatically means the disease is aggressive

High IgM can increase the risk of hyperviscosity syndrome

Treatment is required by clinical guidelines

IgM levels predict cure rates

Question Title

5. Which lab value might make a physician particularly concerned about hyperviscosity syndrome, even if a patient feels well? (Required.)

IgM above 500–600

IgM above 1,000–2,000

IgM above 5,000–6,000

IgM above 10,000

Question Title

6. Which of the following therapies are commonly used as initial treatment options for WM? (Required.)

Bendamustine plus rituximab (BR)

BTK inhibitors such as zanubrutinib

Rituximab-based combinations

All of the above

Question Title

7. Which of the following is a key difference between chemoimmunotherapy and BTK inhibitor therapy for WM? (Required.)

BTK inhibitors are given only once.

Chemoimmunotherapy is typically given for a defined period, while BTK inhibitors are often taken continuously as long as they are working and tolerated.

BTK inhibitors require hospitalization.

Chemoimmunotherapy is always more effective.

Question Title

8. A patient wants to avoid frequent infusion appointments and prefers treatment that can be taken at home. Which type of therapy may be especially appealing? (Required.)

Intravenous rituximab-based therapy only

Radiation therapy

BTK inhibitor therapy (oral medication)

Surgery

Question Title

9. Which statement best reflects Dr. Sawalha's approach to discussing treatment options? (Required.)

Physicians should choose the treatment without patient input.

Most patients can be offered multiple options and make decisions collaboratively with their healthcare team.

Cost is the only factor that matters.

Age alone determines treatment.

Question Title

10. Which response category represents the best outcome currently achievable with WM treatment, although it is uncommon? (Required.)

Stable Disease

Partial Response

Very Good Partial Response

Complete Response

Question Title

11. What was one of the key take-home messages from this presentation? (Required.)

Every patient with WM needs treatment right away.

There is one best treatment for all patients.

Treatment decisions should be based on disease factors, urgency, overall health, and patient preferences.

IgM level is the only factor that matters.

Question Title

12. What would be most important to you when considering a WM treatment option? (There is no wrong answer. Dr. Sawalha emphasized that treatment decisions should be individualized and aligned with each patient's goals and priorities.) (Required.)

Convenience and lifestyle fit

Potential side effects

Speed and depth of response

All of the above

Other (please specify)

Navigating Initial Treatment Options Quiz

Question Title

* 1. A newly diagnosed WM patient feels well, has no significant symptoms, and has stable blood counts. What is the most likely recommendation? (Required.)

Question Title

* 2. Why do WM specialists often recommend monitoring instead of immediate treatment for patients without symptoms? (Required.)

Question Title

* 3. Which of the following may be a reason to start treatment for WM? (Required.)

Question Title

* 4. A patient's IgM level rises above 6,000 mg/dL, but they have no symptoms. Why might some physicians still discuss treatment? (Required.)

Question Title

* 5. Which lab value might make a physician particularly concerned about hyperviscosity syndrome, even if a patient feels well? (Required.)

Question Title

* 6. Which of the following therapies are commonly used as initial treatment options for WM? (Required.)

Question Title

* 7. Which of the following is a key difference between chemoimmunotherapy and BTK inhibitor therapy for WM? (Required.)

Question Title

* 8. A patient wants to avoid frequent infusion appointments and prefers treatment that can be taken at home. Which type of therapy may be especially appealing? (Required.)

Question Title

* 9. Which statement best reflects Dr. Sawalha's approach to discussing treatment options? (Required.)

Question Title

* 10. Which response category represents the best outcome currently achievable with WM treatment, although it is uncommon? (Required.)

Question Title

* 11. What was one of the key take-home messages from this presentation? (Required.)

Question Title

* 12. What would be most important to you when considering a WM treatment option? (There is no wrong answer. Dr. Sawalha emphasized that treatment decisions should be individualized and aligned with each patient's goals and priorities.) (Required.)

1. A newly diagnosed WM patient feels well, has no significant symptoms, and has stable blood counts. What is the most likely recommendation? (Required.)

2. Why do WM specialists often recommend monitoring instead of immediate treatment for patients without symptoms? (Required.)

3. Which of the following may be a reason to start treatment for WM? (Required.)

4. A patient's IgM level rises above 6,000 mg/dL, but they have no symptoms. Why might some physicians still discuss treatment? (Required.)

5. Which lab value might make a physician particularly concerned about hyperviscosity syndrome, even if a patient feels well? (Required.)

6. Which of the following therapies are commonly used as initial treatment options for WM? (Required.)

7. Which of the following is a key difference between chemoimmunotherapy and BTK inhibitor therapy for WM? (Required.)

8. A patient wants to avoid frequent infusion appointments and prefers treatment that can be taken at home. Which type of therapy may be especially appealing? (Required.)

9. Which statement best reflects Dr. Sawalha's approach to discussing treatment options? (Required.)

10. Which response category represents the best outcome currently achievable with WM treatment, although it is uncommon? (Required.)

11. What was one of the key take-home messages from this presentation? (Required.)

12. What would be most important to you when considering a WM treatment option? (There is no wrong answer. Dr. Sawalha emphasized that treatment decisions should be individualized and aligned with each patient's goals and priorities.) (Required.)